Market Overview

Morgan Stanley Neutral On Natera, Starts At Equal-Weight


In a report published Monday, Morgan Stanley analyst Steve Beuchaw initiated coverage of Natera Inc (NASDAQ: NTRA) with an Equal-weight rating and price target of $20. The analyst expects the company to grow at a CAGR of 25 percent over the next three years into a TAM worth $15 billion, despite pricing pressure on its core business.

Beuchaw believes that "the technology and commercial organization are top-tier but valuation suggests expectations are high," while expecting increased visibility over the next 2-4 years into the company's path to penetrating the combined oncology and prenatal TAM.

The analyst expects Panorama, the company's lead non-invasive prenatal screening product, to see expanding market opportunity in the U.S. over the next 1-3 years, with increased insurance coverage. This is expected to drive over 30 percent growth for Panorama.

In addition, "Natera's cloud-based lab model positions the company to expand into an incremental $2bn TAM in Europe," according to the Morgan Stanley report. Also visibility into Natera's liquid biopsy platform is likely to increase over the next 2-3 years. This non-invasive cancer test has a market opportunity of about $10 billion.

However, the analyst expressed concern regarding the competition in the markets the company operates in.

"Timelines on insurer coverage of NIPS (non-invasive prenatal screening) testing in the low/average risk pregnancy populations are unclear. Liquid biopsy is a nascent field, and clinical trials to prove analytical and clinical value would be completed over the next 2-4 years," Beuchaw added.

Latest Ratings for NTRA

Aug 2019MaintainsBuy
Aug 2019MaintainsBuy
Oct 2018Initiates Coverage OnNeutral

View More Analyst Ratings for NTRA
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Steve BeuchawAnalyst Color Initiation Analyst Ratings


Related Articles (NTRA)

View Comments and Join the Discussion!

Latest Ratings

TORCCantor FitzgeraldDowngrades3.0
CIDMCanaccord GenuityMaintains1.5
TDGCanaccord GenuityMaintains620.0
DLPNCanaccord GenuityMaintains1.6
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Macquarie Prefers Vail Resorts In Ski Stocks Group

Stifel Cuts SFX Entertainment To Hold, Fair Value Is $4